Cargando…

Naturally Occurring PCSK9 Inhibitors

Genetic, epidemiological and pharmacological data have led to the conclusion that antagonizing or inhibiting Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces cardiovascular events. This clinical outcome is mainly related to the pivotal role of PCSK9 in controlling low-density lipoprotei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adorni, Maria Pia, Zimetti, Francesca, Lupo, Maria Giovanna, Ruscica, Massimiliano, Ferri, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284437/ https://www.ncbi.nlm.nih.gov/pubmed/32429343 http://dx.doi.org/10.3390/nu12051440

Ejemplares similares

PCSK9 Induces Rat Smooth Muscle Cell Proliferation and Counteracts the Pleiotropic Effects of Simvastatin
por: Lupo, Maria Giovanna, et al.
Publicado: (2021)

Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease
por: Adorni, Maria Pia, et al.
Publicado: (2019)

PCSK9 induces a pro-inflammatory response in macrophages
por: Ricci, Chiara, et al.
Publicado: (2018)

PCSK9 Affects Astrocyte Cholesterol Metabolism and Reduces Neuron Cholesterol Supplying In Vitro: Potential Implications in Alzheimer’s Disease
por: Papotti, Bianca, et al.
Publicado: (2022)

Lipoprotein(a) and PCSK9 inhibition: clinical evidence
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9
por: Adorni, Maria Pia, et al.
Publicado: (2017)

PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma
por: Fasolato, Silvano, et al.
Publicado: (2020)

PCSK9 Confers Inflammatory Properties to Extracellular Vesicles Released by Vascular Smooth Muscle Cells
por: Greco, Maria Francesca, et al.
Publicado: (2022)

Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acid
por: Ferri, Nicola, et al.
Publicado: (2023)

Impact of Soy β-Conglycinin Peptides on PCSK9 Protein Expression in HepG2 Cells
por: Macchi, Chiara, et al.
Publicado: (2021)

SAT-LB92 Sex Hormones Therapy Differentially Modulates HDL Function in Transgender Individuals
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

NMR, LC-MS Characterization of Rydingia michauxii Extracts, Identification of Natural Products Acting as Modulators of LDLR and PCSK9
por: Sut, Stefania, et al.
Publicado: (2022)

Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis—The IMPROVE Study
por: Coggi, Daniela, et al.
Publicado: (2021)

Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation
por: Palumbo, Marcella, et al.
Publicado: (2022)

PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
por: Carugo, Stefano, et al.
Publicado: (2022)

The Modulation of PCSK9 and LDLR by Supercritical CO(2) Extracts of Mentha longifolia and Isolated Piperitone Oxide, an In Vitro Study
por: Sut, Stefania, et al.
Publicado: (2021)

Phage display for targeting PCSK9
por: Ferri, Nicola
Publicado: (2021)

HDL Cholesterol Efflux and Serum Cholesterol Loading Capacity Alterations Associate to Macrophage Cholesterol Accumulation in FH Patients with Achilles Tendon Xanthoma
por: Adorni, Maria Pia, et al.
Publicado: (2022)

High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives
por: Adorni, Maria Pia, et al.
Publicado: (2021)

Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review
por: Gianazza, Erica, et al.
Publicado: (2023)

Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
por: Ferri, Nicola, et al.
Publicado: (2020)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

Berberine: Ins and outs of a nature-made PCSK9 inhibitor
por: Ataei, Sarina, et al.
Publicado: (2022)

Legacy perfluoro-alkyl substances impair LDL-cholesterol uptake independently from PCSK9-function
por: Sabovic, Iva, et al.
Publicado: (2023)

PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
por: Quagliariello, Vincenzo, et al.
Publicado: (2023)

PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation
por: Dozio, Elena, et al.
Publicado: (2020)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
por: Péč, Martin Jozef, et al.
Publicado: (2023)

HDL Proteome and Alzheimer’s Disease: Evidence of a Link
por: Marsillach, Judit, et al.
Publicado: (2020)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
por: Kosmas, Constantine E, et al.
Publicado: (2020)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
por: Pęczek, Piotr, et al.
Publicado: (2021)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

HDL in COVID-19 Patients: Evidence from an Italian Cross-Sectional Study
por: Papotti, Bianca, et al.
Publicado: (2021)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
por: Tomlinson, Brian, et al.
Publicado: (2021)

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile
por: Lupo, Maria Giovanna, et al.
Publicado: (2021)

Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity
por: Macchi, Chiara, et al.
Publicado: (2022)

Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity: A Cross-sectional Study
por: Marinelli, Carla, et al.
Publicado: (2022)

Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
por: Choi, Jah Yeon, et al.
Publicado: (2019)

Effect of the JAK/STAT Inhibitor Tofacitinib on Macrophage Cholesterol Metabolism
por: Adorni, Maria Pia, et al.
Publicado: (2023)

Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management
por: Waiz, Mohd, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_td0mv23q86t1ob3a9aclp7jmu6